BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Radient Pharmaceuticals Files Patents in Japan and China


10/24/2011 9:57:09 AM

TUSTIN, CA--(Marketwire - October 24, 2011) - Radient Pharmaceuticals Corporation "the Company" or "Radient" (OTCQX: RXPC) (PINKSHEETS: RXPC), a developer and marketer of In Vitro Diagnostic (IVD) cancer tests, today announced it has filed patent applications for its proprietary Onko-Sure® cancer test with the patent offices of Japan and China. Patent protection enhances the Company's distribution channel opportunities in these countries. Filing international patent applications is part of Radient's global strategy to increase the number of markets in which Onko-Sure® is regulatory approved for various indications and patent protected.

"We have been selling Onko-Sure® in Asian countries where we are experiencing continued growth, with consistent re-orders from customers in the region. Japan and China are larger markets, where having patent protection improves our ability to forge productive distribution partnerships for our cancer test," stated Radient Chairman and CEO Douglas MacLellan.

Onko-Sure® is a non-invasive cancer blood test that has been shown, in a large body of published clinical research, to be effective in the detection and treatment monitoring of 19 different cancers. Onko-Sure® is a 96-well ELISA test kit sold to clinical reference labs. Labs run individual tests prescribed by doctors. Serum samples can be run, in duplicate, for 41 individuals, on each test kit.

For additional information on Radient Pharmaceuticals Corporation and its products visit: www.radient-pharma.com or e-mail info@radient-pharma.com. For Investor Relations contact Dilek Mir at: ir@radient-pharma.com or 714-881-0244.

The following table is intended to provide the latest information on Radient's business metrics:

----------------------------------------------------------------------------
Radient's Business Metrics                                                  
                                                                            
----------------------------------------------------------------------------
Cash on hand: $372,255*                                                     
                                                                            
*Approximate amount as of October 19, 2011                                  
                                                                            
----------------------------------------------------------------------------
Common Shares Outstanding: 647 million*                                     
                                                                            
*Approximate number as of October 19, 2011.                                 
                                                                            
 750 million shares authorized.                                             
                                                                            
----------------------------------------------------------------------------
Outstanding Warrants & Options: 111 million*                                
                                                                            
*Approximate number as of October 19, 2011                                  
----------------------------------------------------------------------------

Radient Pharmaceuticals:

Headquartered in Tustin, California, Radient Pharmaceuticals Corporation is dedicated to saving lives and money for patients and global healthcare systems through the deployment of its FDA-cleared In Vitro Diagnostic Onko-Sure® cancer test kit for colorectal cancer treatment and recurrence monitoring. The Company's focus is on the discovery, development and commercialization of unique high-value diagnostic tests that will help physicians answer important clinical questions related to early disease state detection, treatment strategy, and the monitoring of disease progression or recurrence. To learn more about our company, products, and potentially life-saving cancer test, visit www.radient-pharma.com.

Forward-Looking Statements:

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company's operations, markets, services, products, and prices. With respect to Radient Pharmaceuticals Corporation, except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.


Digg this    Bookmark with del.icio.us    Add to Newsvine

Technorati:


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->